Serum undercarboxylated osteocalcin levels are related to bone disease in hemodialysis and peritoneal dialysis patients

Abstract

Objectives: In our study, we investigated whether the undercarboxylated osteocalcin (ucOC) is an indicator of bone turnover for patients treated with hemodialysis (HD) or peritoneal dialysis (PD). Furthermore, we have examined the relationships between ucOC levels and other bone inidicators such as osteocalcin (OC), bone specific alkaline phosphatase (B-ALP), calcitonin, vitamin D, intact parathyroid hormone (iPTH), calcium (Ca), phosphate (P), magnesium (Mg) and bone mineral density (BMD).

Methods: Study group was consisted of 24 HD, 30 PD patients and 30 control subjects. ucOC measurements were based on precipitation of carboxylated OC with barium sulfate. After precipitation, ucOC was measured in supernatant by ELISA.

Results: In chronic kidney disease (CKD), increased ucOC levels were present both in HD and PD groups. The ucOC levels in HD group were higher than those of PD group. ucOC levels in samples after HD were lower than in samples before HD. But there is no difference between groups for ucOC% levels. We observed that ucOC levels for CRF were higher compared to that of control group and statistically significant. ucOC levels were positively correlated with OC, B-ALP, ALP, iPTH, P and Mg levels. There were negative and significant correlations between ucOC levels and BMD values. ucOC has a good discrimination power for both high and low turnover ROD groups.

Conclusions: ucOC is a useful marker to evaluation of bone metabolism in patients undergone hemodialysis or peritoneal dialysis in end-stage renal disease.

Keywords

• Renal bone disease
• Hemodialysis
• Peritoneal dialysis
• Undercarboxylated osteocalcin
• Osteocalcin
• Bone mineral density

References

1. 1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011) 2017;7:1-59.
2. 2. Dhondup T, Qian Q. Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure. Blood Purif 2017;43:179-88.
3. 3. Piraino B, Chen T, Cooperstein L, Serge G, Puschett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 1998;30:57-62.
4. 4. Hutchison AJ, Whitehouse RW, Boulton HF, Adams EJ, Mawer BE, et al. Correlation of bone histology with parathyroid hormone, vitamin D3 and radiology in end-state renal disease. Kidney Int 1993;44:1071-7.
5. 5. Vermeer C, Jie KSG, Knapen MHJ. Role of vitamin K in bone metabolism. Annu Rev Nutr 1995;15:1-22.
6. 6. Saupe J, Shearer MJ, Kohlmeier M. Phylloquinone transport and its influence on gama -carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am J Clin Nutr 1993;58:204-8.
7. 7. Sokoll LJ, Sadowski JA. Comparison of biochemical indexes for assessing vitamin K nutritional status in a healthy adult population. Am J Clin Nutr 1996;63:566-73.
8. 8. Malyszko J, Wolczynski S, Skrzydlewska E, Malyszko JS, MysliwiecM.Vitamin K status in relation to bone metabolism in patients with renal failure. Am J Nephrol 2002;22:504-8.

9. 9. Sokoll L, O’Brien ME, Camilo ME, Sadowski JA. Undercarboxylated osteocalcin: development of a method to determine vitamin K status. Clin Chem 1995;41:1121-8.
10. 10. Koyama N, Ohara K, Yokota H. A one step sandwich enzyme immunoassay for gamma-carboxylated osteocalcin using monoclonal antibodies. J Immunol Methods 1991;139:17-23.
11. 11. Mass DW, Henderson AR, Enzymes: Burtis CA, Ashwood ER (Ed.) Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 2th ed. St. Louis, MO: Elsevier Saunders, 1994:843.
12. 12. Fischer M, Raue F. Measurements of bone mineral density. Q J Nucl Med 1999;43:233-40.
13. 13. Kohlmeier M, Saupe J, Shearer MJ, Schaefer K, Asmus G. Bone health of adullt hemodialysis patients is related K status. Kidney Int 1997;51:1218-21.
14. 14. Nagata Y, Inaba M, Imanishi Y, Okazaki H, Yamada S, et al. Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis. Osteoporos Int 2015;26:1053-61.
15. 15. Kuzniewski M, Fedak D, Dumnicka P, Kapusta M, Stępien E, Chowaniec, et al. Carboxylated and intact osteocalcin predict adiponectin concentration in hemodialyzed patients. Renal Fail 2016;38:451-7.
16. 16. Gundberg CM, Weinstein RS. Multiple immunnoreactive forms of ostecalcin in uremic serum. J Clin İnvest 1986;77:1762-67.
17. 17. Garneo P, Grimaux M, Seguin P, Delmas PD. Characterization of immunreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994;9:255-65.
18. 18. Liach F, Bover J. Renal osteodystrophy in the kidney. In:BrennerBM, Rector FC, Eds. Brenner and Rector’s kidney. Philedelphia, WB Saunders, 1996. p. 2187- 273.
19. 19. Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000;58:2200-5.
20. 20. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bne turnover in patients with predialysis chronic renal failure. Kidney Int 1999;56:1084-93.
21. 21. Szulc P, Chapuy MC, Meunier PJ, Delmas PD. Serum undercarbaxylated osteocalcin is a marker of risk of hip fracture in elderly women. J Clin Invest 1993;91:1769-74.
22. 22. Kim SM, Kim KM, Kim BT, Joo NS, Kim KN, Lee DJ, et al. Correlation of undercarboxylated osteocalcin (ucOC) concentration and bone density with age in healthy Korean women.J Korean Med Sci 2010;25:1171-5.
23. 23. Yamauchi M, Yamaguchi T, Nawata K, Takaoka S, Sugimoto T. Relationships between undercarboxylated osteocalcin and vitamin K intakes, bone turnover, and bone mineral density in healthy women. Clin Nutr 2010;22:434-56.
24. 24. Plantalech L, Guillaumont M, Leclercq M, Delmas PD. Impaired carboxylation of serum osteocalcin in elderly women. J Bone Miner Res 1991;6:1211-16.